ReviewCurrent neuropharmacology2026
Role of Glycerophospholipid Metabolism in Epilepsy.
Review in Current neuropharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Metabolomic identification and analysis of potential biomarkers of febrile seizures.BMC pediatrics · 2026Article
- Dietary Exposure to 2,2',4,4'-Tetrabromodiphenyl Ether (BDE-47) Causes Inflammation in the Liver of Common Carp (International journal of molecular sciences · 2025Article
- Crinis Carbonisatus-Derived Carbon Dot Suspension Alleviates Temporal Lobe Epilepsy.Pharmaceuticals (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epilepsy is a prevalent and severe neurological condition characterized by recurring seizures. It impacts over 70 million individuals worldwide, posing a substantial challenge to public health and placing a heavy burden on society. Glycerophospholipids are an essential component of neuronal cell membranes. Their metabolism is strictly regulated, and maintaining their homeostasis is crucial for the optimal function of the nervous system. Research indicates that disruptions in glycerophospholipid metabolism are commonly detected in patients with epilepsy and animal models. However, the precise molecular mechanisms behind these disruptions remain unclear. Existing evidence indicates that neuroinflammation, oxidative stress, genetic mutations, and ion channel dysfunction are crucial factors contributing to glycerophospholipids imbalance and epilepsy. Further, therapeutic interventions targeting these pathological processes, such as regulating neuroinflammation and oxidative stress or restoring the balance of glycerophospholipid metabolism, may provide new avenues for epilepsy treatment. This review aims to provide an in-depth analysis of the potential mechanisms underlying the relationship between glycerophospholipid metabolism disorders and epilepsy, exploring potential therapeutic targets and diagnostic biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.